Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provides effective low-intensity treatment options. Rational therapy selection strategies that consider individual's risk of therapy-related toxicities and probability of disease control can maximize benefits of available treatments. Studies have demonstrated that fitness level, measured by geriatric assessment can predict therapy-related toxicities, whereas cytogenetic and mutation results correlate with the probability of responses to standard chemotherapy. We are approaching an era when we move from “one size fits all” approach to personalized therapy selection based on geriatric assessment, genetic and molecular profiling.

Original languageEnglish (US)
Pages (from-to)52-61
Number of pages10
JournalCancer Treatment Reviews
Volume75
DOIs
StatePublished - May 2019

Fingerprint

Geriatric Assessment
Acute Myeloid Leukemia
Therapeutics
Drug Approval
Cytogenetics
Molecular Biology
Leukemia
Drug Therapy
Mutation

Keywords

  • Acute myeloid leukemia
  • Genetic profiling
  • Geriatric assessment
  • Molecular mutation
  • Older adults
  • Therapy selection

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{3f13b3120a5e40e9bc7536b5c16b4d88,
title = "Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling",
abstract = "Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provides effective low-intensity treatment options. Rational therapy selection strategies that consider individual's risk of therapy-related toxicities and probability of disease control can maximize benefits of available treatments. Studies have demonstrated that fitness level, measured by geriatric assessment can predict therapy-related toxicities, whereas cytogenetic and mutation results correlate with the probability of responses to standard chemotherapy. We are approaching an era when we move from “one size fits all” approach to personalized therapy selection based on geriatric assessment, genetic and molecular profiling.",
keywords = "Acute myeloid leukemia, Genetic profiling, Geriatric assessment, Molecular mutation, Older adults, Therapy selection",
author = "Bhatt, {Vijaya Raj}",
year = "2019",
month = "5",
doi = "10.1016/j.ctrv.2019.04.001",
language = "English (US)",
volume = "75",
pages = "52--61",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Personalizing therapy for older adults with acute myeloid leukemia

T2 - Role of geriatric assessment and genetic profiling

AU - Bhatt, Vijaya Raj

PY - 2019/5

Y1 - 2019/5

N2 - Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provides effective low-intensity treatment options. Rational therapy selection strategies that consider individual's risk of therapy-related toxicities and probability of disease control can maximize benefits of available treatments. Studies have demonstrated that fitness level, measured by geriatric assessment can predict therapy-related toxicities, whereas cytogenetic and mutation results correlate with the probability of responses to standard chemotherapy. We are approaching an era when we move from “one size fits all” approach to personalized therapy selection based on geriatric assessment, genetic and molecular profiling.

AB - Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provides effective low-intensity treatment options. Rational therapy selection strategies that consider individual's risk of therapy-related toxicities and probability of disease control can maximize benefits of available treatments. Studies have demonstrated that fitness level, measured by geriatric assessment can predict therapy-related toxicities, whereas cytogenetic and mutation results correlate with the probability of responses to standard chemotherapy. We are approaching an era when we move from “one size fits all” approach to personalized therapy selection based on geriatric assessment, genetic and molecular profiling.

KW - Acute myeloid leukemia

KW - Genetic profiling

KW - Geriatric assessment

KW - Molecular mutation

KW - Older adults

KW - Therapy selection

UR - http://www.scopus.com/inward/record.url?scp=85064257235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064257235&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2019.04.001

DO - 10.1016/j.ctrv.2019.04.001

M3 - Review article

C2 - 31003190

AN - SCOPUS:85064257235

VL - 75

SP - 52

EP - 61

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -